Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer
胰腺癌中 CA19.9 的预靶向临床成像
基本信息
- 批准号:10441296
- 负责人:
- 金额:$ 68.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-10 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntibody SpecificityAwardBackground RadiationBiodistributionBiological MarkersBloodBlood TestsClinicalClinical TrialsCompanionsComplicationCyclooctenesDataDevelopmentDiagnosisDiagnosticDiscipline of Nuclear MedicineDiseaseDrug KineticsEarly DiagnosisEvaluationExcretory functionGenetically Engineered MouseGoalsGrowthHealthHumanImageImaging DeviceImaging TechniquesImaging technologyInvestigationLabelLaboratoriesLeadLeadershipLibrariesMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMetabolismMethodologyModalityMonitorOrganPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPerformancePharmacy (field)PositronPositron-Emission TomographyPrognosisRadiationRadiation Dose UnitRadioactiveRadioimmunoconjugateRadioisotopesRadiopharmaceuticalsReactionReportingSafetySeriesSerumSiteStagingStratificationSurface AntigensSurvival RateTechnologyTestingTherapeuticTherapeutic UsesTimeTissuesTumor TissueValidationWhole BloodWorkXenograft ModelXenograft procedurebasecancer cellcancer diagnosisclinical careclinical diagnosisclinical imagingclinical translationcycloadditiondelivery vehicledesigndosimetryfirst-in-humanfluorodeoxyglucosehuman monoclonal antibodiesimaging approachimaging modalityimaging platformimprovedin vivoin vivo evaluationmembermouse modelnoninvasive diagnosisnovelnovel strategiesnovel therapeuticspancreas imagingpancreatic cancer modelpancreatic cancer patientspancreatic ductal adenocarcinoma modelpre-clinicalradioligandresidencerisk minimizationserial imagingsmall moleculetargeted imagingtheranosticstreatment planningtreatment strategytumoruptakevector
项目摘要
PROJECT SUMMARY/ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly lethal disease with a 5-year survival of only
6%. Given the tremendous current focus on the creation of new treatment modalities for pancreatic cancer, the
development of imaging technologies that can safely, accurately, and unambiguously aid in the early
diagnosis, staging, and treatment monitoring of the disease is a vitally important unmet clinical need. While
antibodies have long been attractive vectors for the delivery of diagnostic and therapeutic radioisotopes to
cancer cells, radioimmunoconjugates often give rise to a critical clinical complication: high radiation doses to
non-target organs. In order to circumvent this obstacle, we have recently developed a methodology for
pretargeted PET imaging that harnesses the rapid bioorthogonal cycloaddition between trans-cyclooctene
(TCO) and tetrazine (Tz) to effectively combine the affinity and specificity of antibodies with the rapid
pharmacokinetics of small molecules. This methodology not only distinguishes tumor tissue with very high
contrast, but also produces only a fraction of the background radiation dose to healthy tissue compared to
directly labeled antibodies. This proposal describes the development, preclinical validation, and clinical
translation of a pretargeted strategy for the PET imaging of PDAC.
We will employ the antibody 5B1, a fully human monoclonal antibody (mAb) which targets CA19.9, a well-
established biomarker for pancreatic cancer. Specific Aim 1 (SA1), executed during Years 1-2 of the award
period, will be focused on the design, synthesis, and pharmacokinetic evaluation of a library of 68Ga-labeled Tz
radioligands with the overall goal of identifying four radioligands with the most favorable combination of
stability, reactivity, and pharmacokinetics. Specific Aim 2 (SA2), executed during Years 2-3 of the award
period, will be centered on the in vivo evaluation of pretargeted PET imaging strategies employing these Tz
radioligands and 5B1-TCO in three different murine models of PDAC. The different methodologies will be
evaluated based on tumoral uptake, tumor-to-background activity ratios, and dosimetry metrics, and the
overarching goal of this specific aim is the identification of a strategy suitable for clinical translation. Specific
Aim 3 (SA3), executed during Years 3-5 of the award period, will be focused on the clinical translation of a
pretargeted PET imaging strategy. To this end, an FDA IND will be prepared and submitted for the first-in-
human clinical trial, and the in vivo performance of the methodology will be evaluated in a series of 28 patients
to obtain preliminary imaging data and fundamental biodistribution, metabolism, and safety information. We
believe that this proposal could have a significant near-term impact on the clinical care of patients with
pancreatic cancer by creating a sensitive, safe, and effective diagnostic and theranostic imaging modality.
Furthermore, we contend that this work could also have a long-term, transformational effect on the way
antibodies are used in nuclear medicine, ultimately improving the imaging of a wide field of malignant growths.
项目总结/摘要
胰腺导管腺癌(PDAC)是一种几乎一致致死的疾病,
百分之六鉴于目前对胰腺癌新治疗模式的巨大关注,
发展成像技术,可以安全,准确,明确地帮助早期
该疾病的诊断、分期和治疗监测是一个极其重要的未满足的临床需求。而
抗体长期以来一直是有吸引力的载体,用于将诊断和治疗性放射性同位素递送至
癌细胞,放射免疫缀合物通常引起严重的临床并发症:高辐射剂量,
非靶器官。为了克服这一障碍,我们最近开发了一种方法,
利用反式环辛烯之间的快速生物正交环加成的预靶向PET成像
(TCO)和四嗪(Tz),以有效地将抗体的亲和力和特异性与快速免疫反应联合收割机结合。
小分子的药代动力学。这种方法不仅区分肿瘤组织与非常高的
对比度,但也只产生一小部分的背景辐射剂量的健康组织相比,
直接标记抗体。本提案描述了开发、临床前验证和临床
PDAC的PET成像的预靶向策略的翻译。
我们将使用抗体5 B1,一种靶向CA 19.9的全人单克隆抗体(mAb),一种良好的抗肿瘤抗体。
胰腺癌的生物标志物具体目标1(SA 1),在奖励的第1-2年执行
期间,将集中在设计,合成和药代动力学评价库的68镓标记的Tz
放射性配体,总体目标是鉴定具有以下最有利组合的四种放射性配体
稳定性、反应性和药代动力学。具体目标2(SA 2),在奖励的第2-3年执行
期间,将集中在体内评价的预靶向PET成像策略,采用这些Tz
放射性配体和5 B1-TCO在三种不同的PDAC鼠模型中的作用。不同的方法将是
基于肿瘤摄取、肿瘤与背景活性比和剂量测定指标进行评价,
这一特定目标的首要目标是确定适合临床翻译的策略。具体
目标3(SA 3),在奖励期的第3-5年执行,将专注于临床翻译,
预先靶向PET成像策略。为此,将准备并提交FDA IND,用于首次临床试验。
人体临床试验,并将在一系列28名患者中评价该方法的体内性能
以获得初步的成像数据和基本的生物分布、代谢和安全性信息。我们
我相信,这一建议可能会对患者的临床护理产生重大的近期影响,
通过创建一个敏感,安全和有效的诊断和治疗诊断成像模式,胰腺癌。
此外,我们认为,这项工作也可能有一个长期的,变革性的影响,
抗体被用于核医学,最终改善了广泛的恶性肿瘤的成像。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason S. Lewis其他文献
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
肿瘤摄取铜-二乙酰基-双(N(4)-甲硫缩氨基脲):组织氧合变化的影响。
- DOI:
- 发表时间:
2001 - 期刊:
- 影响因子:9.3
- 作者:
Jason S. Lewis;T. Sharp;R. Laforest;Y. Fujibayashi;M. Welch - 通讯作者:
M. Welch
[Tc(CO)3]+ chemistry: a promising new concept for SPECT?
[Tc(CO)3] 化学:SPECT 的一个有前途的新概念?
- DOI:
10.1007/s00259-003-1293-z - 发表时间:
2003 - 期刊:
- 影响因子:9.1
- 作者:
M. Welch;Jason S. Lewis - 通讯作者:
Jason S. Lewis
68Ga-Labeled DOTA-rhenium cyclized {alpha}-MSH peptide analog: A potential radiopharmaceutical for PET imaging of malignant melanoma
68Ga 标记的 DOTA-铼环化 {α}-MSH 肽类似物:一种用于恶性黑色素瘤 PET 成像的潜在放射性药物
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Lihui Wei;Y. Miao;F. Gallazzi;T. Quinn;M. Welch;Jason S. Lewis - 通讯作者:
Jason S. Lewis
60Cu-ATSM in Cancer of the Uterine Cervix
60Cu-ATSM 在宫颈癌中的应用
- DOI:
- 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
Jason S. Lewis;R. Laforest;F. Dehdashti;P. Grigsby;M. Welch;B. Siegel - 通讯作者:
B. Siegel
H4octapa-trastuzumab: An acyclic chelator-immunoconjugate with superior properties to DOTA for In-111/Lu-177 imaging and therapy
H4octapa-曲妥珠单抗:一种无环螯合剂免疫缀合物,在 In-111/Lu-177 成像和治疗方面具有优于 DOTA 的特性
- DOI:
- 发表时间:
2013 - 期刊:
- 影响因子:0
- 作者:
E. Price;Brian M. Zeglis;Jacqueline Cawthray;Nicholas N. Ramos;C. Ramogida;Jason S. Lewis;M. Adam;C. Orvig - 通讯作者:
C. Orvig
Jason S. Lewis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason S. Lewis', 18)}}的其他基金
Annotating Cancer Biology through Non-Invasive Molecular Imaging
通过非侵入性分子成像注释癌症生物学
- 批准号:
10471612 - 财政年份:2019
- 资助金额:
$ 68.84万 - 项目类别:
Annotating Cancer Biology through Non-Invasive Molecular Imaging
通过非侵入性分子成像注释癌症生物学
- 批准号:
10686347 - 财政年份:2019
- 资助金额:
$ 68.84万 - 项目类别:
Annotating Cancer Biology through Non-Invasive Molecular Imaging
通过非侵入性分子成像注释癌症生物学
- 批准号:
10249950 - 财政年份:2019
- 资助金额:
$ 68.84万 - 项目类别:
Annotating Cancer Biology through Non-Invasive Molecular Imaging
通过非侵入性分子成像注释癌症生物学
- 批准号:
10411426 - 财政年份:2019
- 资助金额:
$ 68.84万 - 项目类别:
Annotating Cancer Biology through Non-Invasive Molecular Imaging
通过非侵入性分子成像注释癌症生物学
- 批准号:
10472042 - 财政年份:2019
- 资助金额:
$ 68.84万 - 项目类别:
Annotating Cancer Biology through Non-Invasive Molecular Imaging
通过非侵入性分子成像注释癌症生物学
- 批准号:
9816661 - 财政年份:2019
- 资助金额:
$ 68.84万 - 项目类别:
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer
胰腺癌中 CA19.9 的预靶向临床成像
- 批准号:
10215431 - 财政年份:2018
- 资助金额:
$ 68.84万 - 项目类别:
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody
使用 89Zrrovalpituzumab(一种 DLL3 靶向单克隆抗体)对高级神经内分泌肺肿瘤进行免疫 PET 成像
- 批准号:
10078772 - 财政年份:2017
- 资助金额:
$ 68.84万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别: